TY - JOUR
T1 - The Effects of Ceruletide in Schizophrenia
AU - Hommer, Daniel W.
AU - Pickar, David
AU - Roy, Alec
AU - Ninan, Philip
AU - Boronow, John
AU - Paul, Steven M.
PY - 1984/6
Y1 - 1984/6
N2 - Eight neuroleptic-resistant schizophrenic patients were treated with ceruletide diethylamine, a cholecystokininlike peptide, in a placebo-controlled, double-blind, cross-over study. Ceruletide or placebo was administered intramuscularly twice a day for four consecutive days while patients received a constant dose of fluphenazine hydrochloride. Cholecystokinin octapeptide was also administered to four different schizophrenic patients in a double-blind, cross-over study. Cholecystokinin or placebo was administered as a slow intravenous infusion daily for four days. There were no changes in either the positive or negative symptoms of schizophrenia between the periods of placebo, ceruletide, or cholecystokinin administration. Furthermore, there was no tendency for the patients' conditions to either improve or worsen during the course of ceruletide or cholecystokinin treatment. In contrast to previous reports from uncontrolled studies, cholecystokininlike peptides appear to be devoid of antipsychotic properties when administered parenterally.
AB - Eight neuroleptic-resistant schizophrenic patients were treated with ceruletide diethylamine, a cholecystokininlike peptide, in a placebo-controlled, double-blind, cross-over study. Ceruletide or placebo was administered intramuscularly twice a day for four consecutive days while patients received a constant dose of fluphenazine hydrochloride. Cholecystokinin octapeptide was also administered to four different schizophrenic patients in a double-blind, cross-over study. Cholecystokinin or placebo was administered as a slow intravenous infusion daily for four days. There were no changes in either the positive or negative symptoms of schizophrenia between the periods of placebo, ceruletide, or cholecystokinin administration. Furthermore, there was no tendency for the patients' conditions to either improve or worsen during the course of ceruletide or cholecystokinin treatment. In contrast to previous reports from uncontrolled studies, cholecystokininlike peptides appear to be devoid of antipsychotic properties when administered parenterally.
UR - http://www.scopus.com/inward/record.url?scp=0021268008&partnerID=8YFLogxK
U2 - 10.1001/archpsyc.1984.01790170091010
DO - 10.1001/archpsyc.1984.01790170091010
M3 - Article
C2 - 6329121
AN - SCOPUS:0021268008
SN - 0003-990X
VL - 41
SP - 617
EP - 619
JO - Archives of General Psychiatry
JF - Archives of General Psychiatry
IS - 6
ER -